{"id":"opc-61815-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NK1 receptor antagonism blocks the effects of substance P, a neuropeptide involved in pain transmission and emesis. By inhibiting this pathway, OPC-61815 may provide therapeutic benefits in conditions mediated by substance P dysregulation, including chemotherapy-induced nausea and vomiting (CINV) and potentially other neuropsychiatric or pain-related disorders.","oneSentence":"OPC-61815 is a selective antagonist of the neurokinin-1 (NK1) receptor that reduces substance P signaling in the central nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:32.186Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV)"}]},"trialDetails":[{"nctId":"NCT05439148","phase":"PHASE1","title":"OPC-61815 in Healthy Chinese Male Subjects","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2022-06-30","conditions":"Healthy Adult Male","enrollment":18},{"nctId":"NCT03962101","phase":"PHASE3","title":"Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2019-06-17","conditions":"Congestive Heart Failure","enrollment":45},{"nctId":"NCT03772041","phase":"PHASE3","title":"Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2019-01-16","conditions":"Congestive Heart Failure","enrollment":294},{"nctId":"NCT03254108","phase":"NA","title":"Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2017-11-06","conditions":"Congestive Heart Failure","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"OPC-61815 injection","genericName":"OPC-61815 injection","companyName":"Otsuka Pharmaceutical Co., Ltd.","companyId":"otsuka","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OPC-61815 is a selective antagonist of the neurokinin-1 (NK1) receptor that reduces substance P signaling in the central nervous system. Used for Chemotherapy-induced nausea and vomiting (CINV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}